RxDoctor Payments Data

Robin Medina-Reinhart, NP

Nurse Practitioner · Fresno, CANPI 1013444165

Payments from drug & device makers

$14,850in general payments, 2019–2025

Across 478 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Amgen$2K
  • AstraZeneca$827
  • Lilly USA, LLC$405
  • Takeda Pharmaceuticals U.S.A., Inc.$380
  • Novo Nordisk$367
  • plus $3K from 39 others

What the payments were for

  • Speaking & faculty fees$6,00040%
  • Food & beverage$8,85060%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,850 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$55,568
Medicare patients
177
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$103,061
MounjaroTirzepatide40$74,531
Repatha SureclickEvolocumab43$51,973
FarxigaDapagliflozin Propanediol35$38,368
JardianceEmpagliflozin32$35,651
RybelsusSemaglutide15$31,491
TrulicityDulaglutide19$19,859
VascepaIcosapent Ethyl25$15,501
LinzessLinaclotide16$13,697
Icosapent Ethyl29$11,459
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,259
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,847
PremarinEstrogens, Conjugated14$7,334
Omega-3 Acid Ethyl Esters37$4,742
Levothyroxine Sodium250$3,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$367$134,55284 claims
Lilly USA, LLCMounjaro, Trulicity$405$94,39059 claims
AstraZenecaFarxiga, Breztri Aerosphere$827$48,62746 claims
Boehringer IngelheimJardiance$130$35,65132 claims
AbbVieLinzess, Synthroid$8,656$15,36233 claims
GSKTrelegy Ellipta$182$9,84714 claims
PfizerPremarin$97$7,33414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →